Overview

Allergic rhinitis is a very common condition (affecting 1 in 5 people in Europe) and a costly one for society (direct and indirect costs). Symptoms vary depending on the time of year, and treatments are primarily symptomatic, with follow-up in ENT consultations. Scientific societies (EAACI, FDA, EMA) recommend using a universal tool (severity score) (the CSMS score, SCST in French) to monitor severity and follow-up, and to obtain consistent data that can be extrapolated to other scientific data (meta-analyses).

Therefore, investigators in the ENT department use this SCST score (as well as others such as the SNOT 22 score) to assess the severity of allergic rhinitis in our patients and its progression.

Tbe investigators wish to confirm the acceptability of this tool for patients, and the statistical value of its properties.

Eligibility

Inclusion Criteria:

• Adult (≥18 years)
• Follow-up at the ENT department of Hautepierre University Hospital for allergic rhinitis

Exclusion Criteria:

• Asymptomatic individuals not requiring follow-up consultations.